Sign up to access all valuation multiples
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
2015
930
LTM Revenue $568M
LTM EBITDA $112M
$754M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, Bioventus reported last 12-month revenue of $568M and EBITDA of $112M.
In the same period, Bioventus generated $409M in LTM gross profit and $46.7M in net income.
See Bioventus valuation multiples based on analyst estimatesIn the most recent fiscal year, Bioventus reported revenue of $573M and EBITDA of $39.2M.
Bioventus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioventus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $568M | XXX | $573M | XXX | XXX | XXX |
| Gross Profit | $409M | XXX | $388M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $112M | XXX | $39.2M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $94.5M | XXX | $26.0M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $46.7M | XXX | -$33.5M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | -6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $294M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bioventus has current market cap of $446M, and EV of $754M.
As of October 17, 2025, Bioventus's stock price is $7.
See Bioventus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $754M | $446M | XXX | XXX | XXX | XXX | $0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialBioventus's trades at 1.3x EV/Revenue multiple, and 19.2x EV/EBITDA.
See valuation multiples for Bioventus and 15K+ public compsAs of October 17, 2025, Bioventus has market cap of $446M and EV of $754M.
Equity research analysts estimate Bioventus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioventus has a P/E ratio of 9.5x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $446M | XXX | $446M | XXX | XXX | XXX |
| EV (current) | $754M | XXX | $754M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 19.2x | XXX | XXX | XXX |
| EV/EBIT | 8.0x | XXX | 28.9x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.5x | XXX | -13.3x | XXX | XXX | XXX |
| EV/FCF | 10.4x | XXX | 19.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioventus's last 12 month revenue growth is 5%
Bioventus's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Bioventus's rule of 40 is 1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioventus's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bioventus and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 1% | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioventus acquired XXX companies to date.
Last acquisition by Bioventus was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioventus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Bioventus founded? | Bioventus was founded in 2015. |
| Where is Bioventus headquartered? | Bioventus is headquartered in United States of America. |
| How many employees does Bioventus have? | As of today, Bioventus has 930 employees. |
| Who is the CEO of Bioventus? | Bioventus's CEO is Mr. Robert E. Claypoole. |
| Is Bioventus publicy listed? | Yes, Bioventus is a public company listed on NAS. |
| What is the stock symbol of Bioventus? | Bioventus trades under BVS ticker. |
| When did Bioventus go public? | Bioventus went public in 2021. |
| Who are competitors of Bioventus? | Similar companies to Bioventus include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bioventus? | Bioventus's current market cap is $446M |
| What is the current revenue of Bioventus? | Bioventus's last 12 months revenue is $568M. |
| What is the current revenue growth of Bioventus? | Bioventus revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Bioventus? | Current revenue multiple of Bioventus is 1.3x. |
| Is Bioventus profitable? | Yes, Bioventus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bioventus? | Bioventus's last 12 months EBITDA is $112M. |
| What is Bioventus's EBITDA margin? | Bioventus's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Bioventus? | Current EBITDA multiple of Bioventus is 6.7x. |
| What is the current FCF of Bioventus? | Bioventus's last 12 months FCF is $72.3M. |
| What is Bioventus's FCF margin? | Bioventus's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Bioventus? | Current FCF multiple of Bioventus is 10.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
